As HDAC6 has been demonstrated to have a causal role in the development of cancer, specific inhibitors have emerged as a promising target for cancer treatment and have been shown to result in decreased cell growth and decreased tumour formation in preclinical studies [44–46]. Here, HDAC6 is linked to neoplasm.